Three different methods for the assay of carcinoembryonic antigen were investigated-radioimmunoassay, enzyme-linked immunoassay, and a commercial immunoradiometric assay. Two standard preparations of CEA were used: the 1st British Standard (73/601) and a commercial preparation obtained as a component of the IRMA kit.
(pH 7·2) containing 50 mg human albumin per 100 mL (assay buffer) and incubated for 24 h at room temperature with 100 J.LL diluted (1:7000) anti-CEA (Dako Immunoglobulins, . Copenhagen, Denmark) and 100 J.LL (400 pg) iodinated CEA (obtained from Professor K Bagshawe, Charing Cross Hospital, London, UK). After incubation, 100 J.l.L of a mixture comprising 14·4 mL assay buffer, 600 J.l.L donkey anti-rabbit serum and 50 J.LL normal rabbit serum was added to each tube. The exact proportions of donkey anti-rabbit and normal rabbit serum depended on the product batch. After standing overnight at 4°C the tubes were centrifuged and the bound radioactivity in the precipitate was counted. At a concentration of 1695 UIL the withinbatch coefficient of variation of a duplicate analysis was 2·5%. The overall precision at 495 UIL was 10·9%. ENZYME were tested by the paired t-test to establish the significance of any differences between methods. Correlation coefficients were also calculated. Differences between methods may be attributable to differences in standard preparations. To test this possibility we compared results obtained by the same methods standardised against the two standards. It was not possible to perform all of the comparisons on the same samples as there was insufficient sample in many instances. The analytical range of the three techniques was not the same and it was necessary to ensure that sample levels fell within the assay range of the techniques being compared.
Results
Significant differences between results were obtained when the different methods were compared ( This was performed using the CEA PRIST kit produced by Pharmacia Diagnostics (Milton Keynes, UK). Test, control or standard sera were incubated with anti-CEA covalently bound to paper. After washing, purified anti-CEA which had been labelled with 125 1 was added and further incubated. The radiolabelled antibody bound via the immobilised CEA was then counted. At a concentration of 278 UIL the within-batch coefficient of variation of a duplicate analysis was 2·7%. The overall precision at 285 UIL was 6·7%.
STANDARDS
Two standard preparations of CEA were used: the 1st British Standard 73/601 obtained from the National Institute of Biological Standards and Control (Holly Hill, London UK)l and a preparation obtained from Pharmacia as a component of their reagent kit. PROCEDURE Serum samples submitted to the laboratory for routine CEA analysis were assayed by RIA, ELISA and IRMA using both the 1st British Standard and the Pharmacia Standards in each system of analysis. Each serum was assayed by at least two methods using the same standards. The results obtained from each pair of methods phosphate-buffered saline containing 0·01% Tween 20 and dried by shaking vigorously.
Standard, control or test sera (100 IJ.L) were added to the wells at timed intervals and allowed to stand at room temperature for 45 min after which the serum was aspirated and replaced by a conjugate of horseradish peroxidase and anti-CEA (Dako Immunoglobulins, Copenhagen, Denmark) diluted 1:1000 in phosphate-buffered saline containing 25% chicken serum and 50 mmoVL sodium citrate.
After a further incubation of 60 min the wells were aspirated and 100 I1L of chromogen (20 mg o-phenylenediamine (Sigma Chemical Company Ltd, Poole, UK) and 10 I1L 30% hydrogen peroxide dissolved in 60 mL citrate buffer, pH 6,0) were added. The colour was allowed to develop for 30 min in the dark and The exception was observed when results obtained by IRMA and RIA were compared using the CEA-PRIST standards. When results were calculated using the two standards in the same assay systems no significant differences were observed (Table 1 ).
Discussion
Highly significant differences were found between results obtained by the three different methods. When the two standard preparations were used in the same assay systems no differences were observed (Table 1 ). We conclude that the differences observed between the different methods are due to the characteristics of the assay systems rather than to differences in the standards.
The RIA is a conventional, homogeneous system in which radiolabelled CEA competes with CEA in the test or standards for binding sites on the antibody. The ELISA is an heterogeneous two-site system in which CEA binds to an immobilised antibody and subsequently antibody--enzyme conjugate reacts with the bound CEA. Two antisera to CEA are used in the IRMA which is also an heterogeneous twosite system. One antiserum is raised in sheep, the other in rabbits. The sheep antiserum is covalently bound to paper to form the solid phase, and the rabbit antiserum, after purification by immunosorbtion, is labelled with 1251. The radiolabelled rabbit antiserum is then used to detect CEA which is bound to the anti-CEApaper complex.
If any non-specific cross-reaction occurs with the anti-CEA used in RIA, this will be measured as CEA and hence falsely elevated concentrations will result. In ELISA where two antibody reactions are employed, even if the first reaction is non-specific it is unlikely that a second non-specific reaction will also occur with the antibody--enzyme conjugate. Two antibody-antigen reactions are also employed in IRMA and so the arguments in favour of a reduction in non-specific cross-reactivity also apply.
When antibodies are raised against any large molecule many antigenic determinants are recognised. Each antibody molecule therefore only recognises a very small part of the antigen molecule. In the IRMA used in this study antibodies were raised in two animal species and hence two families of antibodies will be raised which may not recognise the same determinants. Therefore CEA bound to immobilised antibody may present to the labelled antibody a determinant which may not be recognised and thus the amount of bound antigen will be underestimated.
Antibodies have often been raised against CEA purified from tumour material obtained from an individual patient. CEA is known to exist as a variety of polymorphs.f so identical behaviour against a particular antiserum should Dot be expected from all patient's serum and standard preparations.? Where different antisera are used, differences between assay systems may be accentuated. This seems to be Three methods of CEA analysis 97 particularly so when IRMA and RIA are compared using the two different standards (Fig. 2ab ). The range of concentrations (as assayed by RIA) is wider in Fig. 2a than in Fig.  2b so a larger proportion of raised CEA concentrations from patients with active disease is contained in the study illustrated in Fig. 2a . The antisera used in these two assay systems were raised against CEA purified from metastatic deposits. The immunoreactive species giving rise to the normal concentrations of CEA in many of the subjects in Fig. 2b may not be the same as the CEA produced in raised amounts by the subjects illustrated in Fig. 2a .
Strong arguments exist in favour of performing tests in the hospital where the patient is seen. Clinical liaison is immediate and logistic problems are minimised. The increase in the number of available kits for CEA will encourage more laboratories to attempt this analysis. The results presented in this study sound a cautionary note: proliferation of methods may result in a variety of normal ranges, differing interpretive criteria and increased lack of comparability between methods.
All this may lead to clinical confusion and make the assessment of CEA more difficult. There is not only a need to use recognised standard preparations but also standard methods of analysis using rigidly defined antisera. We suggest therefore that continued use of regional centres for CEA analysis is still necessary.
